ArticlePloS one2025
Global burden of gout among young people from 1990 to 2021, with projections for 2050: A systematic analysis based on the Global Burden of Disease Study 2021.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The gut-joint axis in gout: microbial outer membrane vesicles and mFrontiers in immunology · 2026Review
- Urate dysregulation (hyperuricemia and gout) among people living with HIV: A protocol for a systematic review and meta-analysis.PloS one · 2026Article
- Burden of lip and oral cavity cancer among young people across South, East, and Southeast Asia: trends from 1990 to 2021 and predictions to 2030.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gout represents the most common form of inflammatory arthritis, exerting a substantial impact on patient quality of life and productivity. In recent years, the age distribution of gout has shifted, with an increasing incidence among younger individuals. Accurate statistics regarding the incidence, prevalence, and disability-adjusted life years (DALYs) associated with gout in this population are critical for effective resource allocation in prevention and treatment strategies. In the current study, data from the 2021 Global Burden of Disease (GBD) database were used to analyze the burden of gout among young people aged 15-44 years in 204 countries and territories from 1990 to 2021, with projections extending over the next 25 years. Data on prevalence, incidence, and DALYs were collected and stratified by geographical location, gender, and economic development level. Decomposition analysis and predictive modeling were employed to evaluate trends and the impact of critical indicators. In 2021, 8,516,229 young individuals were affected by gout globally, with 1,975,165 new cases and DALYs totaling 283,725 person-years. Since 1990, the age-standardized prevalence rate, age-standardized incidence rate, and age-standardized DALYs rate increased by 10.4%, 9.4%, and 10.2%, respectively, all showing positive correlation with the sociodemographic index (r = 0.319, 0.272, 0.320, P < 0.001). It is projected that by 2046, global figures in young people will reach approximately 9,229,870 total cases, 2,202,802 new cases, and 307,441 DALYs. Males are anticipated to account for 7,460,349 affected individuals, 1,762,412 new cases, and 245,542 DALYs, whereas females will represent 1,769,521 affected individuals, 440,390 new cases, and 61,899 DALYs. The global disease burden of gout among young people increased significantly from 1990 to 2021, and it is expected to continue rising over the next 25 years. Comprehensive epidemiological data remain essential for guiding gout prevention and management, as well as shaping effective health policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.